keyword
https://read.qxmd.com/read/38627808/repeat-cytoreductive-surgery-with-hipec-for-colorectal-peritoneal-metastases-a-systematic-review
#1
REVIEW
Mina Sarofim, Ruwanthi Wijayawardana, Nima Ahmadi, David L Morris
BACKGROUND: Colorectal peritoneal metastases (CRPM) are present in 10-20% of patients at the time of their initial cancer diagnosis, and affects over 20% of those who develop colorectal cancer recurrence. Cytoreductive surgery (CRS) with HIPEC is firmly established as the optimal surgical treatment, but there is very little known about the benefit of repeat or iterative CRS. The aim of this review is to provide a systematic evaluation of the perioperative complications, survival outcomes and quality of life in patients undergoing repeat CRS with HIPEC for CRPM...
April 17, 2024: World Journal of Surgical Oncology
https://read.qxmd.com/read/38613907/prognostic-value-of-specific-kras-mutations-in-patients-with-colorectal-peritoneal-metastases
#2
JOURNAL ARTICLE
M Tonello, D Baratti, P Sammartino, A Di Giorgio, M Robella, C Sassaroli, M Framarini, M Valle, A Macrì, L Graziosi, F Coccolini, P V Lippolis, R Gelmini, M Deraco, D Biacchi, M Aulicino, M Vaira, S De Franciscis, F D'Acapito, F Carboni, E Milone, A Donini, P Fugazzola, P Faviana, L Sorrentino, E Pizzolato, C Cenzi, P Del Bianco, A Sommariva
BACKGROUND: There is little evidence on KRAS mutational profiles in colorectal cancer (CRC) peritoneal metastases (PM). This study aims to determine the prevalence of specific KRAS mutations and their prognostic value in a homogeneous cohort of patients with isolated CRC PM treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. MATERIALS AND METHODS: Data were collected from 13 Italian centers, gathered in a collaborative group of the Italian Society of Surgical Oncology...
April 12, 2024: ESMO Open
https://read.qxmd.com/read/38611084/progress-in-biological-research-and-treatment-of-pseudomyxoma-peritonei
#3
REVIEW
Xi Li, Guodong Liu, Wei Wu
Pseudomyxoma peritonei (PMP) is a rare disease characterized by extensive peritoneal implantation and mass secretion of mucus after primary mucinous tumors of the appendix or other organ ruptures. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is currently the preferred treatment, with excellent efficacy and safety, and is associated with breakthrough progress in long-term disease control and prolonged survival. However, the high recurrence rate of PMP is the key challenge in its treatment, which limits the clinical application of multiple rounds of CRS-HIPEC and does not benefit from conventional systemic chemotherapy...
April 3, 2024: Cancers
https://read.qxmd.com/read/38607365/skin-conductance-algesimeter-is-unreliable-during-sudden-perioperative-temperature-increases
#4
JOURNAL ARTICLE
Ulf E Kongsgaard, Robin Johansen Menchini, Stein Gunnar Larsen, Knut Erling Juul-Hansen
OBJECTIVES: Pain assessment in anesthetized and non-communicative patients remains a challenge. Clinical signs such as tachycardia, hypertension, sweat and tears, have a low specificity for pain and should therefore ideally be replaced by more specific monitoring techniques. Skin conductance variability has been demonstrated to establish a patients' sensitivity to pain, but may be influenced by temperature changes that leads to profuse sweating. The aim of this pilot study was to test skin conductance changes during sudden temperature changes due to hyperthermic intraperitoneal chemotherapy (HIPEC) perfusation...
January 1, 2024: Scandinavian Journal of Pain
https://read.qxmd.com/read/38604946/incidence-risk-factors-and-outcomes-of-the-transition-of-hipec-induced-acute-kidney-injury-to-acute-kidney-disease-a-retrospective-study
#5
JOURNAL ARTICLE
Yunwei Lu, Ziyan Xiao, Xiujuan Zhao, Yingjiang Ye, Shu Li, Fuzheng Guo, Haiyan Xue, Fengxue Zhu
BACKGROUND: Acute kidney injury (AKI) is recognized as a common complication following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Characterized by prolonged renal function impairment, acute kidney disease (AKD) is associated with a higher risk of chronic kidney disease (CKD) and mortality. METHODS: From January 2018 to December 2021, 158 patients undergoing CRS-HIPEC were retrospectively reviewed. Patients were separated into non-AKI, AKI, and AKD cohorts...
December 2024: Renal Failure
https://read.qxmd.com/read/38604861/the-safety-and-effectiveness-of-prophylactic-hyperthermic-intraperitoneal-chemotherapy-in-patients-with-pathological-t3-4-locally-advanced-colon-cancer
#6
JOURNAL ARTICLE
Taiwei Mo, Xiaofeng Wen, Tuo Hu, Zongjin Zhang, Yaqian Shi, Yongle Chen, Haidong Xiang, Junhua Huang, Zhenyu Xian, Xiaowen He
INTRODUCTION: The safety and effectiveness of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) in pathological T3-4 locally advanced (pT3N + M0 and pT4NxM0) colon cancer (CC) patients with radical resection need further study. METHODS: Clinical and pathological information of pT3-4 locally advanced CC patients who received radical surgery in our hospital from January 2018 to December 2020 were analyzed. The prognosis of patients was estimated using Cox proportional hazards regression analysis and Kaplan-Meier method...
April 10, 2024: Asian Journal of Surgery
https://read.qxmd.com/read/38599315/prophylaxis-and-treatment-of-peritoneal-carcinomatosis-of-gastric-origin-using-hyperthermic-intraperitoneal-chemotherapy-a-systematic-review-and-meta-analysis-of-randomized-trials
#7
REVIEW
Mauro Stefano, Daniele Perrina, Carlo Vallicelli, Luca Ansaloni, Paola Fugazzola, Federico Coccolini, Vanni Agnoletti, Giovanni Luca Frassineti, Alessandro Passardi, Stefano Tamberi, Massimo Framarini, Davide Tassinari, Laura Matteucci, Chiara Sturaro, Graziana Gallo, Fausto Catena
BACKGROUND: Peritoneal carcinomatosis significantly worsens the prognosis of gastric cancer patients. Cytoreduction + HIPEC has shown promising results in the prevention and treatment of peritoneal carcinomatosis in advanced gastric cancer; however, its application remains controversial owing to the variability of the approaches used to perform it and the lack of high-quality evidence. This systematic review and meta-analysis aimed to investigate the role of surgery and HIPEC in the prevention and treatment of peritoneal carcinomatosis of gastric origin...
April 8, 2024: Journal of Gastrointestinal Surgery
https://read.qxmd.com/read/38589714/the-role-of-cytoreductive-surgery-and-hipec-for-the-treatment-of-primary-and-secondary-peritoneal-malignancies-experience-from-a-tertiary-care-center-in-germany
#8
JOURNAL ARTICLE
Mikko Reese, Ann-Kathrin Eichelmann, Tobias M Nowacki, Andreas Pascher, Judith C Sporn
PURPOSE: Peritoneal surface malignancies (PSM) are commonly known to have a dismal prognosis. Over the past decades, novel techniques such as cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and pressurized intraperitoneal aerosol chemotherapy (PIPAC) have been introduced for the treatment of PSM which could improve the overall survival and quality of life of patients with PSM. The decision to proceed with CRS and HIPEC is often challenging due the complexity of the disease, the extent of the procedure, associated side effects, and potential risks...
April 8, 2024: Langenbeck's Archives of Surgery
https://read.qxmd.com/read/38587264/prophylactic-cholecystectomy-is-safe-in-patients-undergoing-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy
#9
JOURNAL ARTICLE
David N Hanna, Nazanin Khajoueinejad, Muhammad O Ghani, Andrew Hermina, Alexander Mina, Christina E Bailey, Noah Cohen, Daniel Labow, Benjamin Golas, Umut Sarpel, Kamran Idrees, Deepa Magge
BACKGROUND: While cholecystectomy is one of the most common operations performed in the United States, there is a continued debate regarding its prophylactic role in elective surgery. Particularly among patients with peritoneal carcinomatosis who undergo cytoreduction surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), further abdominal operations may pose increasing morbidity due to intraabdominal adhesions and potential recurrence. This bi-institutional retrospective study aims to assess postoperative morbidity associated with prophylactic cholecystectomy at the time of CRS-HIPEC...
April 8, 2024: American Surgeon
https://read.qxmd.com/read/38585035/the-cea-pci-ratio-is-a-superior-prognosticator-than-mcorep-for-colorectal-cancer-patients-with-peritoneal-carcinomatosis
#10
JOURNAL ARTICLE
Phelopatir Anthony, Shoma Barat, Nima Ahmadi, David Lawson Morris
BACKGROUND: The CEA/PCI ratio, which evaluates tumour marker and burden, has been demonstrated as a prognosticator for patients with colorectal cancer with peritoneal carcinomatosis. The aim of this study was to compare the CEA/PCI ratio with the Modified Colorectal Peritoneal Score (mCOREP) for overall survival (OS) and recurrence free survival (RFS). There is no literature currently comparing both markers for RFS. METHODS: Data was collected retrospectively for patients undergoing CRS and hyperthermic intraperitoneal chemotherapy (HIPEC) at the Peritonectomy Unit at St...
June 2024: Surgery open science
https://read.qxmd.com/read/38583892/clinical-study-on-simultaneous-resection-of-liver-metastases-combined-with-hyperthermic-intraperitoneal-chemotherapy-for-synchronous-colorectal-cancer-liver-metastasis
#11
RANDOMIZED CONTROLLED TRIAL
Wenxiao Li, Hui Ren, Hongchao Mou, Jie Li, Lijun Dong, Guangjin Li, Mingxuan Xing
PURPOSE: This study aimed to analyze the clinical effect of simultaneous resection of liver metastases combined with hyperthermic intraperitoneal chemotherapy (HIPEC) on synchronous colorectal cancer liver metastasis. METHODS: A total of 144 patients with synchronous colorectal cancer liver metastasis who were admitted to our hospital between January 2018 and January 2019 were randomly assigned into a control group and an intervention group. The patients in the control group received simultaneous resection of liver metastases...
April 2024: Journal of Gastrointestinal Surgery
https://read.qxmd.com/read/38583215/development-of-a-prediction-model-for-recurrence-in-patients-with-colorectal-peritoneal-metastases-undergoing-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy
#12
JOURNAL ARTICLE
Michelle V Dietz, Gerjon Hannink, Ibrahim Said, Femke A van der Zant, Vincent C J van de Vlasakker, Alexandra R M Brandt-Kerkhof, Cornelis Verhoef, Andreas J A Bremers, Johannes H W de Wilt, Patrick H J Hemmer, Ignace H J T de Hingh, Philip R de Reuver, Eva V E Madsen
INTRODUCTION: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival outcomes for selected patients with colorectal peritoneal metastases (PM), but recurrence rates are high. The aim of this study was to develop a tool to predict recurrence in patients with colorectal PM that undergo CRS-HIPEC. MATERIALS AND METHODS: For this retrospective cohort study, data of patients that underwent CRS-HIPEC for colorectal PM from four Dutch HIPEC centers were used...
April 4, 2024: European Journal of Surgical Oncology
https://read.qxmd.com/read/38581939/pancreatic-cancer-with-synchronous-peritoneal-and-hepatic-metastases-a-case-report
#13
Antonios-Apostolos Tentes, Dimitrios Kyziridis, Apostolos Kalakonas, Alexandros Iliadis, Anastasia Fotiadou
UNLABELLED: Introduction and importance: There is evidence that patients with limited peritoneal carcinomatosis of pancreatic cancer or those with low burden of hepatic metastases are amenable to surgical resection. A case report of a patient with cancer of the pancreatic tail and synchronous peritoneal and hepatic metastases is presented. CASE PRESENTATION: A male patient, 66 years old, underwent cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and radio-frequency ablation (RFA) for synchronous hepatic metastases simultaneously to distal pancreatectomy for adenocarcinoma of the pancreas...
March 28, 2024: International Journal of Surgery Case Reports
https://read.qxmd.com/read/38580760/morbidity-and-mortality-of-patients-with-peritoneal-malignancy-following-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#14
JOURNAL ARTICLE
Greta Hotza, Michael Karageorgos, Varvara Pastourmatzi, Nader Baniowda, Dimitrios Kyziridis, Apostolos Kalakonas, Nicolaos Chavouzis, Irene Hotza, Antonios-Apostolos Tentes
BACKGROUND: The purpose of this study was to record the incidence, and identify the prognostic variables of morbidity and mortality in patients with peritoneal malignancy undergoing cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: The files of patients with peritoneal malignancy who underwent CRS + HIPEC from 2015-2022 were retrieved. Morbidity and hospital mortality were recorded and correlated to a variety of clinical variables...
April 5, 2024: Discover. Oncology
https://read.qxmd.com/read/38574044/radical-resection-and-hyperthermic-intraperitoneal-chemotherapy-hipec-in-the-treatment-of-high-risk-recurrent-retroperitoneal-sarcoma-a-pilot-study-in-a-tertiary-asian-centre
#15
JOURNAL ARTICLE
Chin Jin Seo, Joey Wee-Shan Tan, Mohamad Farid, Jolene Si Min Wong, Khee Chee Soo, Claramae Shulyn Chia, Chin-Ann Johnny Ong
BACKGROUND: Peritoneal sarcomatosis (PS) is a difficult entity to treat with limited options and guarded prognosis. We aimed to determine if the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) could offer superior local recurrence-free survival in patients with retroperitoneal sarcoma at high risk of developing PS as opposed to extended resection alone. METHODS: This is a single arm, phase II intervention study where all patients with recurrent localized retroperitoneal sarcoma considered at high risk of developing PS were considered for enrolment (ClinicalTrials...
2024: PloS One
https://read.qxmd.com/read/38558874/-in-vitro-3d-microfluidic-peritoneal-metastatic-colorectal-cancer-model-for-testing-different-oxaliplatin-based-hipec-regimens
#16
JOURNAL ARTICLE
Aras Emre Canda, Tolga Sever, Gizem Calibasi Kocal, Yasemin Basbinar, Hulya Ellidokuz
OBJECTIVES: Treatment of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is still evolving. Conducting a randomized trial is challenging due to the high heterogeneity in the presentation of peritoneal disease and various surgical approaches. Biological research may facilitate more rapid translation of information into clinical practice. There is an emerging need for a preclinical model to improve HIPEC treatment protocols in terms of drug doses and treatment durations...
March 2024: Pleura and peritoneum
https://read.qxmd.com/read/38558873/implementation-of-eras-guidelines-in-patients-undergoing-crs-and-hipec-need-for-multicentre-trial
#17
JOURNAL ARTICLE
Christos Iavazzo, Ioannis D Gkegkes, John Spiliotis
No abstract text is available yet for this article.
March 2024: Pleura and peritoneum
https://read.qxmd.com/read/38558871/peritoneal-metastases-from-rare-ovarian-cancer-treated-with-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-crs-hipec
#18
JOURNAL ARTICLE
Luis Felipe Falla-Zuniga, Armando Sardi, Mary Caitlin King, Felipe Lopez-Ramirez, Philipp Barakat, Carol Nieroda, Teresa Diaz-Montes, Vadim Gushchin
OBJECTIVES: There are limited treatment options and no consensus on the management of advanced rare ovarian malignancies. Rare ovarian malignancies can present with peritoneal metastases (PM), featuring a similar presentation to more common ovarian subtypes. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is an effective treatment for PM of non-gynecologic origin and, recently, epithelial ovarian cancer. We evaluated the feasibility of CRS/HIPEC in the management of PM from rare ovarian malignancies and report postoperative outcomes on these patients...
March 2024: Pleura and peritoneum
https://read.qxmd.com/read/38558870/outcomes-of-minimal-access-cytoreductive-surgery-m-crs-and-hipec-epic-vs-open-cytoreductive-surgery-o-crs-and-hipec-epic-in-patients-with-peritoneal-surface-malignancies-a-meta-analysis
#19
REVIEW
Ajinkya Pawar, Vikas Warikoo, Abhijeet Salunke, Mohit Sharma, Shashank Pandya, Amol Bhardwaj, Sandeep Ks, Jebin Aaron
INTRODUCTION: Minimal Access Surgery (MAS) has shown better peri-operative outcomes with equivalent oncological outcomes in gastrointestinal and thoracic oncology. Open CRS (O-CRS) procedure accompanies inevitable and significant surgical morbidity in patients. The aim of the review article is to compare outcomes of M-CRS and HIPEC/EPIC with open procedure in peritoneal surface malignancies. CONTENT: Comprehensive search of databases was done and total 2,807 articles were found (2793-PubMed and 14-Cochrane review)...
March 2024: Pleura and peritoneum
https://read.qxmd.com/read/38556598/aso-visual-abstract-expanding-the-use-of-hipec-in-ovarian-cancer-at-the-time-of-interval-debulking-surgery-to-figo-stage-iv-after-six-cycles-of-neoadjuvant-chemotherapy-a-prospective-analysis-of-perioperative-and-oncologic-outcomes
#20
JOURNAL ARTICLE
Valentina Ghirardi, Rita Trozzi, Francesca Romana Scanu, Diana Giannarelli, Francesco Santullo, Barbara Costantini, Angelica Naldini, Camilla Panico, Luciano Frassanito, Giovanni Scambia, Anna Fagotti
No abstract text is available yet for this article.
March 31, 2024: Annals of Surgical Oncology
keyword
keyword
693
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.